KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Operating Leases (2019 - 2025)

Sarepta Therapeutics has reported Operating Leases over the past 7 years, most recently at $199.4 million for Q4 2025.

  • Quarterly results put Operating Leases at $199.4 million for Q4 2025, up 3.59% from a year ago — trailing twelve months through Dec 2025 was $199.4 million (up 3.59% YoY), and the annual figure for FY2025 was $199.4 million, up 3.59%.
  • Operating Leases for Q4 2025 was $199.4 million at Sarepta Therapeutics, down from $215.0 million in the prior quarter.
  • Over the last five years, Operating Leases for SRPT hit a ceiling of $215.0 million in Q3 2025 and a floor of $35.2 million in Q3 2022.
  • Median Operating Leases over the past 5 years was $132.0 million (2023), compared with a mean of $117.0 million.
  • Biggest five-year swings in Operating Leases: tumbled 48.35% in 2021 and later skyrocketed 282.5% in 2023.
  • Sarepta Therapeutics' Operating Leases stood at $41.5 million in 2021, then soared by 38.7% to $57.6 million in 2022, then surged by 144.82% to $141.0 million in 2023, then surged by 36.54% to $192.5 million in 2024, then increased by 3.59% to $199.4 million in 2025.
  • The last three reported values for Operating Leases were $199.4 million (Q4 2025), $215.0 million (Q3 2025), and $214.4 million (Q2 2025) per Business Quant data.